title: Proteomics perturbations promoted by the protein kinase CK2 inhibitor quinalizarin.
abstract: A SILAC analysis performed on HEK-293T cells either treated or not for 3h with the CK2 inhibitor quinalizarin (QZ) led to the quantification of 53 phosphopeptides whose amount was reduced by 50% or more by QZ. These phosphopeptides include altogether 69 phosphoresidues, a large proportion of which (almost 50%) are generated by CK2, while the others do not conform to the CK2 consensus. Intriguingly QZ treatment also promotes a 50% or more increase of 108 phosphopeptides including altogether 117 phosphoresidues, 30% of which conform to the CK2 consensus. Here we disclose two mechanisms by which the level of certain phosphosites can be increased rather than decreased by QZ: one relies on the uneven dephosphorylation rate of phosphoresidues close to each other, causing, upon CK2 blockage, the decrease/disappearance of bis-phosphorylated peptides paralleled by the rise of one of its two singly phosphorylated derivatives; the other reflects the increased cellular concentration of a subset of proteins whose expression is substantially up-regulated by QZ treatment. These proteins do not include CK2 itself, whose subunit level is unaffected by QZ. They do include instead a number of substrates whose phosphorylation is increased upon QZ treatment, as well as several kinase/phosphatase regulators and a large number of components of the ribosomal and proteasomal machinery, a circumstance that may partially account for side effects of QZ not directly executed by CK2. Especially remarkable is the finding that all the components of the proteasomal catalytic core and of the PA28 complex committed to the degradation of the non-ubiquitinated proteins are increased, while those of the regulatory complex 19S conferring the ability to degrade the ubiquitinated proteins are unaffected. This article is part of a Special Issue entitled: Inhibitors of Protein Kinases.
authors.affiliation: Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy; Proteomics Center of Padova University, Via G. Orus 2/B, 35129 Padova, Italy.
authors.forename: Cinzia
authors.initials: C
authors.lastname: Franchin
authors.affiliation: Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy.
authors.forename: Mauro
authors.initials: M
authors.lastname: Salvi
authors.affiliation: Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy; Proteomics Center of Padova University, Via G. Orus 2/B, 35129 Padova, Italy. Electronic address: giorgio.arrigoni@unipd.it.
authors.forename: Giorgio
authors.initials: G
authors.lastname: Arrigoni
authors.affiliation: Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy. Electronic address: lorenzo.pinna@unipd.it.
authors.forename: Lorenzo A
authors.initials: LA
authors.lastname: Pinna
mesh_terms: D000880:Anthraquinones / Q000494:pharmacology*; D047390:Casein Kinase II / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D010748:Phosphopeptides / Q000096:biosynthesis* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D040901:Proteomics
chemical_list: D000880:Anthraquinones; D010748:Phosphopeptides; D047428:Protein Kinase Inhibitors; C543211:1,2,5,8-tetrahydroxy anthraquinone; D047390:Casein Kinase II
keywords: CK2; Casein kinase 2; Phosphoproteome; Proteasome; Protein kinase inhibitor; Quinalizarin